Search

A test was conducted to assess the efficacy and safety of emtricitabine as compared to stavudine in combination with didanosine and efavirenz. It was found that drug, emtricitabine administered once daily showed greater virological efficacy, steady response and tolerability as compared to stavudine administered twice daily combined with didanosine and efavirenz.

Stavudine will not be effective in HIV patients whose virus has more than one gene mutation for resistance to zidovudine. This probably occurs because resistance to zidovudine also confers resistance to stavudine.

The AIDS drugs stavudine and didanosine appear to be effective when used together. In a study of 86 HIV patients, higher doses were most effective in suppressing the virus and increasing the number of CD4 T cells.

Stavudine may be safe in the treatment of HIV infection in young children. Researchers assigned 212 children 3 months to 6 years of age to treatment with stavudine or zidovudine. Children treated with stavudine had better weight gain, less reduction in CD4+ white cell levels, and less depression of neutrophilic white cell levels. Tolerance and safety of both drugs were similar. Stavudine may be appropriate as antiretroviral therapy for HIV disease in children., Objectives. To compare the safety and tolerance of stavudine (d4T) versus zidovudine (ZDV, AZT) in symptomatic human immunodeficiency virus-infected children 3 months to 6 years of age. Methods. In an initially double-blind trial, 212 evaluable human immunodeficiency virus-infected children who had received no more than 6 weeks of previous antiretroviral therapy were randomized to receive either d4T (1 mg/kg orally every 12 hours, maximum 40 mg orally every 12 hours) or zidovudine (180 mg/[m.sup.2] orally every 6 hours, maximum 200 mg orally every 6 hours). The study was unblinded after a median follow-up period of 6.3 months; median follow-up at study closure was 17.3 months. Tolerance, safety, disease progression, and immunologic responses were evaluated. Results. The patient population was young (median age, 1.2 years; range, 0.3 to 6.4 years), with a median baseline CD4+ lymphocyte count of 965 cells/[micro]L (range, 18 to 4238 cells/[micro]L). Neutropenia [is less than] 400/[micro]L occurred significantly more commonly among zidovudine recipients (1-year event rates of 20% both up to the time of unblinding and throughout the entire study) than among children receiving d4T (1-year event rates of 5% up to the time of unblinding and 6% throughout the entire study). In exploratory activity analyses using all data collected until study closure, children treated with d4T showed consistently greater positive changes from baseline in weight-for-age-and-gender z scores. As expected in this population of young children, median absolute CD4+ lymphocyte counts decreased in both treatment groups. Smaller changes from baseline were noted among d4T recipients. Conclusions. In children between the ages of 3 months and 6 years, d4T and zidovudine are largely comparable in terms of safety and tolerance. Neutropenia occurs significantly less commonly among children treated with d4T. There was evidence that weight gain and absolute CD4+ lymphocyte counts were better maintained in children receiving d4T. Pediatrics 1998,101:214-220; stavudine, zidovudine, HIV infection, infant or child., ABBREVIATIONS. HIV, human immunodeficiency virus; ZDV, zidovudine; d4T, stavudine; AIDS, acquired immunodeficiency syndrome; ALT, alanine aminotransferase. Antiretroviral therapy of human immunodeficiency virus (HIV)-infected children results in a variety of virologic, [...]